At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
RH Genotype Matched Red Cells for Patients With Sickle Cell Disease and Anti-D
In Brief
A Early Phase 1 clinical trial evaluating D+ RH genotype matched red cell units for transfusion for Sickle Cell Disease and Anti-D Antibodies. Completed, enrolled 5 participants across 1 site.
Detailed Summary
This is a pilot study to evaluate the feasibility and safety of providing RH genotype matched D+ Red Blood Cells (RBCs) to chronically transfused patients with sickle cell disease (SCD) who type D+ but have formed anti-D and are currently transfused with D- RBC (Red Blood Cell) units.
Study Details
Timeline
Interventions
Chronically transfused patients with SCD and anti-D will receive D+ RH genotyped matched red cell units for transfusion in addition to standard C, E, and K antigen matching and being hemoglobin S negative, which is the Children's Hospital of Philadelphia institutional standard of care for patients with SCD. RH genotyping of donor units will be performed by the New York Blood Center (NYBC) Immunogenetics laboratory.